Instead, we propose that the observed inhibition of p38 and ERK1/2 activity in prostate cancer cells is a secondary effect of CuC1 treatment, potentially resulting from various biological mechanisms that warrant further investigation. This evidence concerns the gene MAPK3 and prostate cancer.